Fundraising FoxForesite Capital — 2016 Investments
5 investments dated 2016 · listed companies and verified rows first · show all
Arbutus is a biotechnology company developing therapeutic assets and bringing them to market, with expertise spanning scientific, clinical, operational, and financial development.
BiotechHealthtechWarminster, US
William H. Collier(President and Chief Executive Officer)inGaston Picchio(Chief Development Officer)inMichael J. McElhaugh(Chief Business Officer)inDavid C. Hastings(Chief Financial Officer)inMichael J. Sofia(Chief Scientific Officer)inElizabeth Howard(Executive Officer)in
Celldex is a biotechnology company developing therapeutics across therapeutic areas including immunology and inflammation.
BiotechHealthtechHampton, US
Anthony S. Marucci(Executive Officer, Director)inAvery W. Catlin(Executive Officer)
BoardRichard van den Broek(Director)Timothy M. Shannon, M. D.(Director)Herbert J. Conrad(Director)Karen Shoos(Director)
Madrigal Pharmaceuticals is a biopharmaceutical company developing treatments for metabolic-associated steatohepatitis (MASH).
BiotechHealthtechMedical DevicesConshohocken, US
Rebecca Taub(Founder and Director)inMarc R. Schneebaum(Executive Officer)inPaul A. Friedman(Executive Officer, Director)inBill Sibold(President and Chief Executive Officer)inMardi Dier(Executive Vice President and Chief Financial Officer)inCarole Huntsman(Executive Vice President and Chief Commercial Officer)in
Co-investorsAvoro Capital AdvisorsBay City Capital
Tarsa Therapeutics developed TBRIA, an oral formulation of calcitonin for treating postmenopausal osteoporosis in women more than five years post menopause when other treatments are unsuitable.
BiotechPhiladelphia, US
David Brand(Executive Officer, Director)inGregory Lumpkin(Executive Officer)
BoardRichard Kollender(Director)Martin Edwards(Director)Eric Bednarski(Director)Derek Ferguson(Director)
Board seatJames Tananbaum· per SEC Form D
Co-investorsMVM Life Science PartnersOxford Finance LLCQuaker BioVentures
Biopharmaceutical company developing innovative therapies for chronic diseases using proprietary drug delivery systems.
BiotechBoston, US
James Ahlers(Executive Officer)John Yee(Executive Officer)Sunita Zalani(Executive Officer)Raymond T. Keane(Executive Officer)Thomas Alessi(Executive Officer)Owen Hughes, Jr.(Executive Officer)
Co-investorsBay City CapitalCloudStone CapitalCycad Group LLCMarkerNXT VenturesAlta Partners+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.